Fluorescein

Fluorescein

SCHEMBL1290366

NCCCCCN.O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 9/20 0.81
MAPT P10636 4/20 0.81
MEN1 O00255 4/20 0.81
KMT2A Q03164 4/20 0.81
TDP1 Q9NUW8 3/20 0.81
HTT P42858 2/20 0.81
HPGD P15428 2/20 0.81
RECQL P46063 2/20 0.81
BLM P54132 2/20 0.81
PRMT1 Q99873 2/20 0.81
ACE2 Q9BYF1 2/20 0.81
CYP2C19 P33261 1/20 0.81
SMAD3 P84022 1/20 0.81
LMNA P02545 3/20 0.57
GPR55 Q9Y2T6 2/20 0.57
ALOX12 P18054 2/20 0.57
POLB P06746 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CYP3A4 P08684 2/20 0.54
ALDH1A1 P00352 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorescein SCHEMBL3038291 0.99 FTO (0.79) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL4807011 0.99 FTO (0.82) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL1290524 0.94 FTO (0.87) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL17867543 0.91 FTO (0.97) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL18630551 0.90 FTO (0.81) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL27087693 0.90 FTO (0.94) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL1198361 0.90 FTO (0.94) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL30272223 0.90 FTO (1.00) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL29371199 0.90 FTO (1.00) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL29388667 0.90 FTO (1.00) FTOMAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4348347-A2 SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION Irradiant Technologies Inc. (US) 2024-04-10 EP claimed
CN-117813548-A System and method for high resolution three-dimensional nanofabrication 光辉科技股份有限公司 2024-04-02 CN claimed
CN-117530285-A Sterilization composition 华东理工大学 2024-02-09 CN claimed
WO-2022251546-A2 SYSTEM AND METHOD FOR HIGH RESOLUTION 3D NANOFABRICATION Irradiant Technologies Inc. (US) 2022-12-01 WO claimed
EP-2686022-B1 IMPROVED GLYCAN ARRAYS AND METHODS FOR THEIR FABRICATION OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU SEMIOTIK (RU) 2018-08-22 EP claimed
US-9494515-B2 Glycan arrays and methods for their fabrication Obschestvo s organichennoy oivetstvennostyu “SEMIOTIK” (RU) 2016-11-15 US claimed
EP-2686022-A1 IMPROVED GLYCAN ARRAYS AND METHODS FOR THEIR FABRICATION Obschestvo s Ogranichennoy Otvetstvennostyu "Semiotik" (RU) 2014-01-22 EP claimed
CN-103402548-A Improved glycan arrays and methods of making the same OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU SYNTHAUR 2013-11-20 CN claimed
US-20130288928-A1 GLYCAN ARRAYS AND METHODS FOR THEIR FABRICATION OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "SEMIOTIK" (RU) 2013-10-31 US claimed
WO-2012091606-A1 IMPROVED GLYCAN ARRAYS AND METHODS FOR THEIR FABRICATION OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "SYNTHAUR" (RU) 2012-07-05 WO claimed
EP-0853680-B1 METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER EMD BIOSCIENCES INC (US) 2004-03-31 EP claimed
EP-0853680-A4 METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER NOVAGEN INC (US) 2000-09-13 EP claimed
EP-0853680-A1 METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER NOVAGEN, INC. (US) 1998-07-22 EP claimed
WO-1997012994-A1 METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER NOVAGEN, INC. (US) 1997-04-10 WO claimed
WO-2024148174-A1 PEPTIDE SEQUENCER OREGON HEALTH & SCIENCE UNIVERSITY (US) 2024-07-11 WO disclosed
WO-2024059954-A1 THIOL-ENE HYDROGEL ALLARTA LIFE SCIENCE INC. (CA) 2024-03-28 WO disclosed
US-20240101733-A1 MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOF UNIVERSITé LAVAL (CA) 2024-03-28 US disclosed
CN-1214348-A Divalent reactive water-soluble polymer derivative and complex containing the same MITSUBISHI CHEM CORP (JP) 1999-04-21 CN disclosed
EP-0903152-A2 Bifunctional water-soluble polymer derivative and complex containing it MITSUBISHI CHEMICAL CORPORATION (JP) 1999-03-24 EP disclosed
WO-1998015829-A1 ANALYSIS OF CARBOHYDRATES AMERSHAM INTERNATIONAL PLC (GB) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101733-A1 MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOF PLA2G2A, PHOSPHO1, PLA2G4A FTO 4601/4885MAPT 2180/4885MEN1 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.